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Background: Guidelines recommend fibrinolysis for STEMI patients who cannot achieve primary percutaneous coronary intervention (pPCI) within 
120 minutes of first contact. Yet, current use of fibrinolytic therapy among contemporary STEMI patients in the United States is unclear.
methods: From ACTION Registry-GWTG between 7/2008-3/2012, we identified 12,852 fibrinolytic-eligible STEMI patients first evaluated at a non-
pPCI hospital then transferred to a pPCI center 30 -120 min drive time away (5th percentile of fibrinolysis and 95% percentile of pPCI respectively).
results: A total of 5,254 patients (41%) received pretransfer fibrinolysis and 7,598 patients underwent pPCI. Patients receiving fibrinolysis had 
similar clinical characteristics compared with those receiving pPCI (Table). Referral hospitals that used fibrinolysis had longer drive times to PCI 
centers than those that transferred for pPCI. Guideline-recommended time goals were achieved in <50% of patients reperfused with either strategy. 
After fibrinolysis, 42% required rescue PCI and 27% more underwent subsequent PCI at a median of 19 hours (IQR 8-34) later. There was no 
significant difference in associated in-hospital mortality between fibrinolysis and pPCI (3.8 vs. 3.9%, adjusted OR 1.15, 95%CI 0.94-1.40).
conclusion: Fibrinolysis remains a viable reperfusion strategy for eligible patients in the US. However, timeliness of reperfusion regardless of 
strategy remains a target for improvement for transferred STEMI patients. 
Fibrinolysis (n=5254)
Primary PCI 
(n = 7598)
p-value
Patient characteristics
Age, median (% ≥65 years) 59 (32.2%) 59 (35.4%) 0.023 (<0.001)
Female 26.5% 26.8% 0.73
Non-white race 11.8 8.8% <0.001
Diabetes 20.5% 22.8% 0.002
Prior MI 18.3% 17.8% 0.48
Prior heart failure 3.7% 4.2% 0.16
Prior stroke 3.4% 4.2% 0.03
CrCl, median (IQR), ml/min 90 (68-116) 91 (67-119) 0.03
ACTION mortality risk score, median (IQR) 31 (26-37) 32 (27-38) 0.002
Door to needle, median (IQR) 34 (23-52) -- --
Door to balloon, median (IQR) -- 129 (106-170) --
Hospital characteristics
Referral hospital bed size, median (IQR) 89 (49-142) 91 (47-142) 0.41
Door-in-door-out time, median (IQR) 85 (63-116) 60 (42-88) <0.001
Drive time to pPCI hospital, median (IQR) 64 (49-84) 50 (40-65) <0.001
